Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Sanara MedTech Inc.NASDAQ: SMTI
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 14.4% from a year ago
Net receivables stood at $13.62M at the end of Q1 FY2026, up 14.4% from a year earlier and up 13.5% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Net receivables amounted to 19.7% of total assets at the end of Q1 FY2026, up 7.3 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +14.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 12M USD
- Year-over-year change
- -11.5%
- 4-year CAGR
- +41.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12M | -11.5% |
| FY2024 | 2024-12-31 | 13.55M | +58.8% |
| FY2023 | 2023-12-31 | 8.53M | +21.8% |
| FY2022 | 2022-12-31 | 7M | +134.2% |
| FY2021 | 2021-12-31 | 2.99M | — |
Net Receivables vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.4% is the 4th highest of 10, against a peer median of +12.4%.
- Net receivables amounts to 19.7% of total assets for SMTI, versus a peer median of 13.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $175.41M USD | +14.2% | +10.0% | 13.0% | |
| Mar 2026 | $53.02M USD | -10.2% | +1.0% | 13.0% | |
| Mar 2026 | $31.18M USD | +16.4% | +18.4% | 15.8% | |
| Mar 2026 | $15.77M USD | +7.1% | +21.3% | 30.4% | |
| Mar 2026 | $13.62M USD | +14.4% | +19.7% | 19.7% | |
| Mar 2026 | $10.6M USD | +12.4% | -13.7% | 9.7% | |
| Mar 2026 | $9.86M USD | -3.3% | +48.6% | 14.1% | |
| Mar 2026 | $9.62M USD | +122.5% | +25.9% | 17.8% | |
| Apr 2026 | CA$7.72M CAD | +180.5% | -10.8% | 2.2% | |
| Mar 2026 | $2.29M USD | +11.9% | — | 0.7% | |
| Peer median (excluding SMTI) | — | +12.4% | +14.2% | 13.0% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18.65M | 8.96M | 5.15M | 15.88M | 16.58M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.99M | 7M | 8.53M | 13.55M | 12M |
| Inventory | 2.05M | 3.55M | 4.72M | 2.75M | 3.95M |
| Other Current Assets | 0 | 1.1M | 608.41K | 1.12M | 1.02M |
| Total Current Assets | 24.61M | 20.62M | 19.01M | 33.31M | 33.54M |
| Property, Plant & Equipment (Net) | 2.04M | 2.22M | 3.25M | 1.88M | 2.53M |
| Goodwill | 0 | 3.6M | 3.6M | 3.6M | 3.6M |
| Intangible Assets | 4.73M | 31.51M | 44.93M | 41.01M | 18.64M |
| Long-term Investments | 5.02M | 3.08M | 3.08M | 8.3M | 14.63M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 11.79M | 40.42M | 54.87M | 54.79M | 39.4M |
| Total Assets | 36.4M | 61.04M | 73.87M | 88.09M | 72.94M |
| Account Payables | 593.97K | 1.43M | 2M | 1.5M | 2.34M |
| Short-term Debt | 0 | 0 | 580.36K | 0 | 353.23K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 2.05M | 0 | 1.23M |
| Other Current Liabilities | 0 | 1.16M | (947.68K) | 0 | 235K |
| Total Current Liabilities | 6.02M | 12.81M | 13.77M | 15.29M | 18.63M |
| Long-term Debt | 0 | 0 | 9.11M | 30.69M | 45.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 6M | 4.66M | 1.96M | 548.13K |
| Total Non-current Liabilities | 222.15K | 6.51M | 15.52M | 33.89M | 48.39M |
| Total Liabilities | 6.24M | 19.32M | 29.28M | 49.18M | 67.01M |
| Common Stock | 7.68K | 8.3K | 8.54K | 8.75K | 8.95K |
| Retained Earnings | (15.24M) | (23.39M) | (28.04M) | (37.78M) | (75.3M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | (8.67K) |
| Minority Interest | (488.4K) | (107.56K) | (244.26K) | (491.61K) | (8.67K) |
| Total Equity | 30.15M | 41.72M | 44.59M | 38.91M | 5.93M |
| Total Debt | 425.44K | 819.22K | 11.79M | 32.29M | 48.19M |
| Net Debt | (18.23M) | (8.14M) | 6.64M | 16.41M | 31.61M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.